Veraxa Biotech Holding AG
VRXAHealthcare|Biotechnology|DE
$0.95
-0.00 (-0.23%)
About
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.
Stock Price
-92.2%(1Y)
1M
-12.8%
3M
-52.3%
6M
-92.2%
YTD
-92.2%
1Y
-92.2%
3Y
-92.2%
5Y
-92.2%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$134.3M
Employees0
CEOChristoph Antz
IPO DateJun 9, 2026
Beta0.26
52-Week Range$0.9 – $27.36
Avg Volume466,172
ExchangeNASDAQ
Websiteveraxa.com
Ownership
Float8.9%
Shares Outstanding141.4M
Recent Insider Trades
Gruninger MarcBUY
Oct 28, 20269,133 shares @ $1.00
Gruninger MarcBUY
Oct 27, 2026867 shares @ $0.98
Ziegler Christoph SamuelBUY
Oct 20, 202630,000 shares @ $1.09
Willener Raju SudirOTHER
Sep 1, 20260 shares
Baumann Oliver RolfBUY
Aug 27, 202650,000 shares @ $1.50
Recent News
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
Oct 13, 2026 · globenewswire.com
Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
Oct 7, 2026 · barrons.com
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
Oct 7, 2026 · globenewswire.com
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Sep 4, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:40 AM